Amgen (CHIX:AMGD) Other Long-Term Liabilities: €2,046 Mil (As of Mar. 2026)


CHIX:AMGD Amgen Inc CHIX:AMGD
90 GF Score
Price €285.00
GF Value €325.97
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Amgen Other Long-Term Liabilities?

Amgen CHIX:AMGD 90 Other Long-Term Liabilities is €2,046 Mil as of Mar. 2026. GuruFocus rates CHIX:AMGD with a GF Score™ of 90/100 and a GF Value™ of €325.97 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Amgen's other long-term liabilities for the quarter that ended in Mar. 2026 was €2,046 Mil.

Amgen's quarterly other long-term liabilities increased from Sep. 2025 (€1,894 Mil) to Dec. 2025 (€2,031 Mil) and increased from Dec. 2025 (€2,031 Mil) to Mar. 2026 (€2,046 Mil).

Amgen's annual other long-term liabilities increased from Dec. 2023 (€2,133 Mil) to Dec. 2024 (€2,243 Mil) but then declined from Dec. 2024 (€2,243 Mil) to Dec. 2025 (€2,031 Mil).

Amgen Other Long-Term Liabilities Related Terms

Amgen Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Amgen's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Other Long-Term Liabilities Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,181.53 2,502.54 2,132.94 2,243.30 2,030.81

Amgen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,044.25 2,025.31 1,894.00 2,030.81 2,045.73
CHIX:AMGD
90GF Score
Amgen Inc CHIX:AMGD
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of €2,046 Mil mean?
Amgen (CHIX:AMGD) has a Other Long-Term Liabilities of €2,046 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Amgen and its competitors.
Is Amgen's Other Long-Term Liabilities too high?
Amgen's current Other Long-Term Liabilities is €2,046 Mil. Overall, Amgen has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Other Long-Term Liabilities compare to GILD and PFE?
Amgen's Other Long-Term Liabilities of €2,046 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Amgen and its competitors. Amgen's current Other Long-Term Liabilities is €2,046 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (CHIX:AMGD) is currently considered Modestly Undervalued. The stock's GF Value™ is €325.97, compared to a current price of €285.00 — trading 12.6% below its estimated fair value. The current Other Long-Term Liabilities is €2,046 Mil. Amgen's overall GF Score™ is 90/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current Other Long-Term Liabilities is €2,046 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (CHIX:AMGD) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be undervalued. The current stock price of €285.00 is trading 12.6% below its estimated GF Value™ of €325.97. GuruFocus considers Amgen to be Modestly Undervalued.

Key valuation signals for CHIX:AMGD:

  • Other Long-Term Liabilities: €2,046 Mil
  • GF Value™: €325.97 vs. price of €285.00 (12.6% below fair value)
  • GF Score™: 90/100 with 8 warning signs

No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
90GF Score

Get the complete analysis for CHIX:AMGD

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€285.00
Price
€325.97
GF Value